Gene expression during successful implantation in a natural cycle
To access this article, please choose from the options below
I.V.V. has nothing to disclose. R.M. has nothing to disclose. L.V.L. has nothing to disclose. P.D. has received grant support from Merck, Schering Plough, Ferring, IBSA, Besins, Anecova. L.G. is a consultant for Repros Therapeutics, Quest Diagnostics, EMD Serono, Biosante, Vantia Therapeutics, and Bayer Schering Pharma; and owns stock in Pfizer. C.B. has nothing to disclose.
Supported by grant AL405 from Research Foundation-Flanders (FWO), Belgium, and by National Institute of Child Health and Human Development/National Institutes of Health, Bethesda, MD, through a cooperative agreement U54HD055764-02 (LCG) as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research.
PII: S0015-0282(09)03596-1
doi:10.1016/j.fertnstert.2009.08.057
© 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

